Abstract
The review of Alvarez et al. on the controversial role of bevacizumab in the treatment of advanced breast cancer, presented in this issue of
The Oncologist
, is examined.
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
This output has contributed to the advancement of the following goals:
Source: InCites